Paclitaxel

A helical stent to treat peripheral artery disease without extensive lesion preparation was safe and effective at 2 years in a real-world population with long and complex lesions, a speaker reported.

In a new meta-analysis covering more than 7,000 patients with peripheral artery disease, there was no association between paclitaxel-coated devices and all-cause mortality, researchers reported.

At 5 years, there was no link between a paclitaxel-coated balloon and excess mortality compared with percutaneous transluminal angioplasty in two studies of patients with peripheral artery disease.

A low-dose paclitaxel-coated balloon was similar to a higher-dose paclitaxel-coated balloon in safety and efficacy among patients with femoropopliteal lesions at 2 years, according to new data from the COMPARE trial.

The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients with gastric cancer and peritoneal metastases, according to study results presented at Gastrointestinal Cancers Symposium.

Despite the phase 3 study IPATunity130 demonstrating negative results, the presentation of the data at San Antonio Breast Cancer Symposium 2020 will still be “interesting,” according to Nancy U. Lin, MD.

In this video, Megan Kruse, MD, a medical oncologist at Cleveland Clinic, spoke with Healio about findings from the IPATunity130 trial.

An interim analysis of the SWEDEPAD trial, which was paused after a meta-analysis detected a mortality hazard associated with paclitaxel-coated devices, found no death risk from the devices in patients with peripheral artery disease.

Healio and Cardiology Today have aggregated the most-read news from the virtual VIVA 20.

In a pooled analysis of two randomized controlled trials of a low-dose paclitaxel-coated balloon to treat peripheral artery disease, there was no mortality difference between the paclitaxel-coated balloon and an uncoated balloon at 4 years.